{"meta":{"query_hash":"08c60bd9815f","filters":{"venue":"Core evidence"},"cohort_total":4,"direct_labels_cover":0,"predictions_cover":4,"exported":4,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/08c60bd9815f","api":"https://metacan.xera.ac/api/v1/cohort?venue=Core+evidence"},"results":[{"id":"W1972864082","doi":"10.2147/ce.s42568","title":"An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies","year":2013,"lang":"en","type":"article","venue":"Core evidence","topic":"Cell death mechanisms and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":84,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Pharmacology; Leukemia; Lymphoma; Adverse effect; Venetoclax; Oncology; Cancer research; Immunology; Chronic lymphocytic leukemia","score_opus":0.07430101011301232,"score_gpt":0.3242971822992617,"score_spread":0.24999617218624937,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1972864082","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00008701826,0.9989911,0.0000627056,0.00020210522,0.00016800506,0.000018957813,0.000054045195,0.000004592212,0.00041149333],"genre_scores_gemma":[0.0006748436,0.9984669,0.00017375746,0.00031743463,0.00013594619,0.000022418619,0.0000794994,0.0000012200625,0.00012796576],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99943525,0.0001424423,0.00019628806,0.00006537412,0.00013294427,0.000027641021],"domain_scores_gemma":[0.99845433,0.0008228438,0.00034349484,0.000024148307,0.0002877755,0.00006739726],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0011610913,0.0010273145,0.0027304539,0.0034809804,0.00031869303,0.001186266,0.0016283339,0.0012049174,0.006844776],"category_scores_gemma":[0.002687795,0.00033035738,0.0018555173,0.0041508456,0.00032878702,0.0010983931,0.0006469384,0.0013585582,0.0013357856],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00039961573,0.00008545856,0.00021556686,0.29625145,0.0011017293,0.00022652795,0.00006619716,0.0002880146,0.0009421825,0.001188245,0.036960855,0.6622742],"study_design_scores_gemma":[0.00028497627,0.00048393555,0.0031601149,0.20320353,0.007799751,0.0017618058,0.000119254604,0.00019522298,0.0004721021,0.0016610507,0.7808076,0.000050734805],"about_ca_topic_score_codex":0.0013735474,"about_ca_topic_score_gemma":0.0027662434,"teacher_disagreement_score":0.006844776,"about_ca_system_score_codex":0.0008642643,"about_ca_system_score_gemma":0.001943716,"threshold_uncertainty_score":0.022898078},"labels":[],"label_agreement":null},{"id":"W2044171598","doi":"10.2147/ce.s40698","title":"Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections","year":2014,"lang":"en","type":"review","venue":"Core evidence","topic":"Antibiotic Resistance in Bacteria","field":"Biochemistry, Genetics and Molecular Biology","cited_by":167,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Manitoba; Shared Health","funders":"","keywords":"Ceftazidime/avibactam; Avibactam; Ceftazidime; Medicine; Pharmacology; Tolerability; Microbiology; Pseudomonas aeruginosa; Adverse effect; Biology","score_opus":0.12105615346282708,"score_gpt":0.4038837467701463,"score_spread":0.2828275933073192,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2044171598","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00011735058,0.9993011,0.00006536603,0.0001299318,0.000071950446,0.000007956199,0.00002682957,0.0000034546688,0.00027602926],"genre_scores_gemma":[0.00060899934,0.9988971,0.0001586907,0.00010748502,0.00006485791,0.000008665064,0.000032755986,9.459178e-7,0.000120457786],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9996371,0.000071392744,0.0001068121,0.000050399736,0.00011038433,0.000023910063],"domain_scores_gemma":[0.99928075,0.00036681438,0.00014594542,0.000012218402,0.00016055207,0.000033714157],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008453437,0.0008772175,0.0017791933,0.003038066,0.0002337807,0.0010625325,0.00080841826,0.00093162345,0.0036077814],"category_scores_gemma":[0.0014094885,0.00031841453,0.0011413019,0.0034655638,0.00029363166,0.00089546724,0.0005010441,0.0010274599,0.00092378375],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00023321953,0.00009531104,0.00023707755,0.14509733,0.00050985516,0.00022226007,0.00007895243,0.00032547774,0.0014593698,0.0012506346,0.018117532,0.83237296],"study_design_scores_gemma":[0.00011625211,0.00045482646,0.0029437405,0.06091033,0.0026804584,0.0022062687,0.00012902908,0.0002589695,0.00081139716,0.0013800067,0.9280563,0.000052558433],"about_ca_topic_score_codex":0.0013451505,"about_ca_topic_score_gemma":0.0024309498,"teacher_disagreement_score":0.0036077814,"about_ca_system_score_codex":0.00054423086,"about_ca_system_score_gemma":0.0016126612,"threshold_uncertainty_score":0.012069225},"labels":[],"label_agreement":null},{"id":"W2060750200","doi":"10.2147/ce.s7031","title":"Carbidopa/levodopa/entacapone: the evidence for its place in the treatment of Parkinson’s disease","year":2009,"lang":"en","type":"article","venue":"Core evidence","topic":"Parkinson's Disease Mechanisms and Treatments","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Centre for Movement Disorders","funders":"","keywords":"Entacapone; Dyskinesia; Levodopa; Carbidopa; Parkinson's disease; Medicine; Tolerability; Ropinirole; Adverse effect; Aromatic L-amino acid decarboxylase; Dopamine; Pramipexole; Pharmacology; Catechol-O-methyl transferase; Anesthesia; Internal medicine; Disease; Chemistry","score_opus":0.18869641609488635,"score_gpt":0.39317053505880145,"score_spread":0.2044741189639151,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2060750200","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.016374132,0.9736574,0.00016840608,0.004235382,0.00041500395,0.000023684273,0.000090691494,0.000013226029,0.005022032],"genre_scores_gemma":[0.21578588,0.77189094,0.0014324152,0.005965444,0.0020675207,0.000065735374,0.00025988487,0.000018694656,0.0025135572],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.999548,0.00013900037,0.00008252339,0.000056998808,0.00012148282,0.000051826784],"domain_scores_gemma":[0.998035,0.0007449043,0.00058633654,0.00004972907,0.0004392388,0.00014480525],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014975372,0.0003894609,0.00076939637,0.00060163,0.0002565616,0.0010835598,0.00046625745,0.0008090845,0.003195776],"category_scores_gemma":[0.0021505102,0.00011007519,0.00075294875,0.00061556604,0.0005662833,0.00064280094,0.00033198146,0.0014778853,0.00049711065],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.009190785,0.0005412287,0.006876451,0.008111558,0.000784777,0.00060561893,0.00007160186,0.00022583951,0.0066849496,0.0022192057,0.008768686,0.9559193],"study_design_scores_gemma":[0.010696617,0.024964744,0.102046,0.038278766,0.008240691,0.010571726,0.00061581616,0.0013538095,0.023646878,0.010159432,0.76918584,0.00023966315],"about_ca_topic_score_codex":0.0011995872,"about_ca_topic_score_gemma":0.0031601547,"teacher_disagreement_score":0.003195776,"about_ca_system_score_codex":0.00070705585,"about_ca_system_score_gemma":0.0008458928,"threshold_uncertainty_score":0.010690868},"labels":[],"label_agreement":null},{"id":"W2793091729","doi":"10.2147/ce.s133661","title":"Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis","year":2018,"lang":"en","type":"review","venue":"Core evidence","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Probity Medical Research; SKiN Health; Queen's University; University of British Columbia","funders":"","keywords":"Dupilumab; Atopic dermatitis; Medicine; Dermatology","score_opus":0.18114665579964437,"score_gpt":0.41802296174934195,"score_spread":0.23687630594969758,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2793091729","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00009494793,0.99936825,0.000029297815,0.00013412221,0.00009907024,0.000013990535,0.000037765985,0.0000026256546,0.0002200075],"genre_scores_gemma":[0.00088936597,0.99855083,0.00010863297,0.00021707384,0.0000828096,0.00001549703,0.00004685999,0.0000010138721,0.00008798498],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.9993662,0.00015182576,0.00019748406,0.000075967895,0.00017043421,0.000037993057],"domain_scores_gemma":[0.9982109,0.0010544736,0.00034227915,0.000025681833,0.00030950285,0.000057173755],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0014758819,0.0009889704,0.0029322656,0.0039651426,0.00031150316,0.0014585569,0.0013496141,0.0012607103,0.004960077],"category_scores_gemma":[0.0028988118,0.00037406513,0.002356644,0.0038320974,0.00033061384,0.0010011375,0.0006903592,0.0012306501,0.0007965538],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0004909964,0.00007789084,0.00022092469,0.34329173,0.0015386381,0.00018994247,0.00009011032,0.0002630559,0.0007234587,0.0010914861,0.018789753,0.63323194],"study_design_scores_gemma":[0.0003978776,0.00073326234,0.0038770714,0.34380773,0.015737876,0.0016605203,0.00020105552,0.00024609675,0.00059433316,0.0018566785,0.6308185,0.00006890467],"about_ca_topic_score_codex":0.0021267708,"about_ca_topic_score_gemma":0.004429467,"teacher_disagreement_score":0.004960077,"about_ca_system_score_codex":0.00097178534,"about_ca_system_score_gemma":0.0021451388,"threshold_uncertainty_score":0.016593158},"labels":[],"label_agreement":null}]}